Postoperative Hip Precautions After Total Hip Arthroplasty Via the Posterior Approach: A Prospective Randomized Trial
Launched by RUSH UNIVERSITY MEDICAL CENTER · Feb 15, 2016
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how certain instructions, called hip precautions, can affect patients after they have surgery to replace their hip joint. These precautions are meant to help prevent the new hip from dislocating in the first six weeks after surgery. The study will also explore how these precautions impact patients' ability to return to their daily activities and their overall satisfaction with the surgery. Additionally, the researchers will assess whether these precautions are cost-effective for patients.
To participate in this study, you need to be between 65 and 74 years old and be planning to have a total hip replacement surgery due to non-inflammatory arthritis. It’s important that you can understand and follow the study guidelines. If you have allergies to the materials used in the study or have had previous surgeries on the same hip (other than a minor procedure), you may not be eligible. If you join, you can expect to be closely monitored and receive guidance on your recovery process while contributing to valuable research that could help future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing a primary total hip arthroplasty via the posterior approach by participating attending surgeons at this institution
- • Index diagnosis of noninflammatory arthritis
- • Patients must be able to understand and comply with study procedures
- Exclusion Criteria:
- • Allergy or intolerance to the study materials
- • History of previous surgeries on the affected joint other than arthroscopy; i.e. revision THA or open surgeries
About Rush University Medical Center
Rush University Medical Center is a leading academic medical institution located in Chicago, Illinois, dedicated to advancing healthcare through innovative research and clinical trials. As a sponsor of numerous clinical studies, Rush focuses on translating scientific discoveries into effective treatments and improving patient outcomes across a variety of medical disciplines. With a commitment to excellence in patient care, education, and research, Rush leverages its state-of-the-art facilities and a robust network of specialists to conduct comprehensive trials that adhere to the highest ethical and regulatory standards. Through collaboration with a diverse patient population, Rush aims to enhance the understanding of diseases and develop novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Omar Behery, MD
Principal Investigator
Orthopedics Surgeon
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials